137830-77-4

Usage

Uses

Due to the limited information available on 2-Methyl-[1,2,6]thiadiazinane 1,1-dioxide, its applications are not clearly defined. However, based on its chemical structure and the general properties of organosulfur compounds, it can be speculated that it may have potential uses in various industries. These potential applications could include:
Used in Pharmaceutical Industry:
2-Methyl-[1,2,6]thiadiazinane 1,1-dioxide could be used as a building block or intermediate in the synthesis of pharmaceutical compounds, given its unique chemical structure and the presence of a thiadiazinane ring.
Used in Chemical Research:
2-METHYL-[1,2,6]THIADIAZINANE 1,1-DIOXIDE may serve as a subject of study in chemical research, particularly in the field of organosulfur chemistry, to explore its reactivity, stability, and potential applications in various chemical reactions.
Used in Material Science:
2-Methyl-[1,2,6]thiadiazinane 1,1-dioxide could potentially be used in the development of new materials, such as polymers or catalysts, due to its heterocyclic structure and the presence of a sulfur atom.

Upstream product

• 6291-84-5 N-Methyl-1,3-propanediamine 
• 7803-58-9 SULFAMIDE 

Downstream Products

• 1092980-96-5 C₁₀H₁₂FN₃O₄S 
• 1193318-34-1 C₃₂H₃₅N₃O₅S₂ 

Relevant academic research and scientific papers

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

Carbazole-containing sulfonamides and sulfamides: Discovery of cryptochrome modulators as antidiabetic agents

A series of novel carbazole-containing sulfonamides and sulfamides were synthesized. A structure-activity relationship study of these compounds led to the identification of potent cryptochrome modulators. Based on the results of efficacy studies in diet-induced obese (DIO) mice, and the desired pharmacokinetic parameters, compound 41 was selected for further profiling.

HETEROARYLS AND USES THEREOF

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

HETEROARYLS AND USES THEREOF

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, L1, L2, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Carbazole-Containing Sulfonamides as Cryptochrome Modulators

The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.

Novel lβ-methylcarbapenems having cyclic sulfonamide moieties: Synthesis and evaluation of in-vitro biological activity - Part II

The synthesis of a new series of 1β-methylcarbapenems having cyclic sulfonamide moieties is described. Their in-vitro antibacterial activities against both Gram-positive and Gram-negative bacteria were tested and the effect of a substituent on the pyrroli

Synthesis and antibacterial activities of novel oxazolidinones having cyclic sulfonamide moieties

The synthesis of a new series of oxazolidinones having cyclic sulfonamide moieties is described. Their in vitro antibacterial activities against both Gram-positive and Gram-negative bacteria were tested and the effect of substituents on the oxazolidinone

Novel lβ-methylcarbapenems having cyclic sulfonamide moieties: Synthesis and evaluation of in vitro antibacterial activity

The synthesis of a new series of 1β-methylcarbapenems having cyclic sulfonamide moieties is described. Their in vitro antibacterial activities against both Gram-positive and Gram-negative bacteria were tested and the effect of substituent on the pyrrolidi

Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors

Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the

Synthesis and Biological Activity of 3--5--1H-indole and Analogues: Agonists for the 5-HT1D Receptor

A novel series of 5-(1,1-dioxo-1,2,5-thiadiazolidin-2-yl)tryptamines was designed, synthesized, and evaluated as 5-HT1D receptor agonists.Compounds such as 8d,f,k were identified which had comparable affinity, potency, and receptor selectivity